TPST240517P2500
- 0.05
- 0.000.00%
Tempest Therapeutics Newsroom
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 1368.75% HC Wainwright & Co. → $47 Reiterates Buy → Buy 03/20/2024 1368.75% HC Wainwright & Co.
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical Advancements
Tempest Therapeutics | 10-Q: Quarterly report
Tempest Therapeutics 1Q Loss/Shr 36c >TPST
Tempest Therapeutics 1Q Loss/Shr 36c >TPST
Express News | Tempest Therapeutics Inc: Expects to Have Sufficient Resources to Fund Operations Into Q2 of 2025
Express News | Tempest Therapeutics Q1 Net Income USD -7.904 Million Vs. Ibes Estimate USD -7.62 Million
Express News | Tempest Therapeutics Q1 EPS USD -0.36 Vs. Ibes Estimate USD -0.37
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
PDF Version Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual M
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PDF Version BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune
Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
PDF Version BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
Tempest Announces Publication of Positive Data From Phase 1 Trial of TPST-1120 in Patients With Advanced Solid Tumors in Journal of Cancer Research Communications
PDF Version TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive r
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics (TPST) Receives a Buy From Scotiabank
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents
Financial ResultsYear End 2023Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. The increase was primarily due to proceeds from t